Sign up to save your podcasts
Or
Share Barbara Burtness, MD - The Pan-Tumor Perspective: Looking Toward the Future of Care With HER3-Directed ADCs for Pretreated Patients With Advanced Solid Tumors
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Barbara Burtness, MD - The Pan-Tumor Perspective: Looking Toward the Future of Care With HER3-Directed ADCs for Pretreated Patients With Advanced Solid Tumors
Please visit answersincme.com/DDP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human epidermal growth factor receptor 3 (HER3)–directed antibody–drug conjugates (ADCs) for the treatment of patients with advanced solid tumors. Upon completion of this activity, participants should be better able to: Explain the rationale for the pan-tumor use of HER3-directed treatment for patients with locally advanced or metastatic solid tumors; Review clinical trials of investigational HER3-directed ADCs in previously treated patients with advanced solid tumors; and Outline criteria that may guide the selection of HER3-directed ADCs to treat advanced solid tumors, based on available evidence.
View all episodes
By Answers in CME
5
55 ratings
Please visit answersincme.com/DDP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human epidermal growth factor receptor 3 (HER3)–directed antibody–drug conjugates (ADCs) for the treatment of patients with advanced solid tumors. Upon completion of this activity, participants should be better able to: Explain the rationale for the pan-tumor use of HER3-directed treatment for patients with locally advanced or metastatic solid tumors; Review clinical trials of investigational HER3-directed ADCs in previously treated patients with advanced solid tumors; and Outline criteria that may guide the selection of HER3-directed ADCs to treat advanced solid tumors, based on available evidence.
More shows like CME in Minutes: Education in Oncology & Hematology
View all
JAMA Editors' Summary
131 Listeners
NEJM This Week
325 Listeners
Journal of Clinical Oncology (JCO) Podcast
38 Listeners
This Week in Cardiology
864 Listeners
JAMA Clinical Reviews
493 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
JAMA Medical News
90 Listeners
CME in Minutes: Education in Cardiology & Pulmonology
3 Listeners
CME in Minutes: Education in Dermatology
3 Listeners
CME in Minutes: Education in Primary Care
5 Listeners
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
4 Listeners
CME in Minutes: Education in Ophthalmology
0 Listeners